Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13126731 | 1.00 | LMNA (0.34) | LMNAALDH1A1CA12CA2CA7 | |
| SCHEMBL13126726 | 0.85 | CA2 (0.33) | LMNAALDH1A1CA12CA2CA7 | |
| SCHEMBL17226609 | 0.80 | GRIN2D (0.48) | LMNAALDH1A1CA12CA2CA7 | |
| SCHEMBL1160739 | 0.79 | LMNA (0.36) | LMNAALDH1A1CA12CA2CA7 | |
| SCHEMBL13195555 | 0.79 | LMNA (0.36) | LMNAALDH1A1CA12CA2CA7 | |
| SCHEMBL1406851 | 0.79 | LMNA (0.36) | LMNAALDH1A1CA12CA2CA7 | |
| SCHEMBL19808594 | 0.77 | LMNA (0.34) | LMNAALDH1A1CA12CA2CA7 | |
| SCHEMBL19798641 | 0.75 | LMNA (0.39) | LMNAALDH1A1CA12CA2CA7 | |
| SCHEMBL26027255 | 0.75 | LMNA (0.36) | LMNAALDH1A1CA12CA2CA7 | |
| SCHEMBL25509287 | 0.75 | GRIN2D (0.32) | LMNAEPHX2GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | LMNA 4813/4885ALDH1A1 2128/4885CA12 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.